In a significant milestone for medical technology and sleep medicine, Belgium-based Nyxoah has officially commenced its BREATHE post-approval study in the United States. The trial, designed to evaluate the real-world performance of the Genio system—a cutting-edge, leadless hypoglossal nerve stimulation therapy—marks a pivotal moment in the company’s efforts to solidify its footprint in the American market following FDA approval.
The first patient has been successfully implanted with the Genio device by Dr. Rolando Molina, an otolaryngologist at South Florida ENT Associates. This inaugural procedure signals the beginning of an ambitious, multi-year research endeavor that aims to track the efficacy and safety of the technology across a broad spectrum of clinical settings.
The BREATHE Study: Scope and Objectives
The BREATHE trial is a single-arm, prospective study designed to generate high-quality, real-world evidence (RWE). As medical devices move from the controlled environment of clinical trials to routine clinical practice, the need for comprehensive post-market surveillance becomes paramount.
Study Design and Methodology
Nyxoah intends to enroll up to 229 patients across 25 high-profile clinical sites throughout the United States. The study is intentionally inclusive of a diverse range of medical environments, involving both specialized sleep medicine physicians and expert ear, nose, and throat (ENT) surgeons. By broadening the scope of practitioners, the study aims to capture data that reflects the "everyday" reality of treating moderate to severe obstructive sleep apnea (OSA).
Dr. Edward Mezerhane, a sleep medicine physician at the PharmaDev Clinical Research Institute, is serving as the site principal investigator. His role, alongside other lead clinicians, is to ensure that the data collection process adheres to rigorous scientific standards over the study’s five-year duration.
Primary Endpoints and Safety Assessment
The BREATHE study is built upon a foundation of measurable clinical outcomes. Researchers are focusing on two co-primary effectiveness endpoints, both to be evaluated at the 12-month mark:
- Apnoea-Hypopnea Index (AHI): The standard metric for measuring the severity of sleep apnea by counting the number of pauses in breathing per hour of sleep.
- Oxygen Desaturation Index (ODI): A measurement of how often blood oxygen levels drop during sleep, providing critical insight into the cardiovascular stress placed on the patient.
Beyond effectiveness, safety remains the paramount concern. The study protocol mandates the assessment of device-related and procedure-related serious adverse events at the 12-month interval, with continued monitoring on an annual basis thereafter until the conclusion of the five-year follow-up period.
A Chronology of Innovation: From BLAST to BREATHE
The journey of the Genio system is a testament to the evolution of neurostimulation technology. Understanding the context of the BREATHE study requires a look back at the developmental milestones that paved the way for its current US deployment.
- 2019: CE Mark Achievement: The Genio system first gained international recognition when it received its CE Mark, supported by the foundational BLAST OSA study. This initial success validated the technology’s core promise: a leadless, battery-free approach to treating OSA.
- Expansion of Indications: Following the initial approval, Nyxoah conducted the BETTER SLEEP study, which provided the evidence needed to expand the therapy’s scope, specifically for patients suffering from Complete Concentric Collapse (CCC)—a challenging anatomical condition that often renders other treatments ineffective.
- 2024: The DREAM IDE Milestone: The company’s momentum accelerated in 2024 when Nyxoah reported highly favorable results from the DREAM Investigational Device Exemption (IDE) pivotal study. These findings were instrumental in demonstrating to regulators that the Genio system could offer a safe and effective alternative for the millions of Americans suffering from sleep-disordered breathing.
- 2025: FDA Approval: The culmination of these efforts occurred in August 2025, when the US Food and Drug Administration (FDA) granted approval for the Genio system. This regulatory green light cleared the path for commercialization and the subsequent launch of the BREATHE post-approval study.
The Technology: Why Genio Represents a Shift in Paradigm
Obstructive sleep apnea is a pervasive condition characterized by the collapse of the upper airway during sleep. Traditionally, Continuous Positive Airway Pressure (CPAP) therapy has been the gold standard. However, patient compliance rates with CPAP remain notoriously low due to discomfort, mask leaks, and the psychological burden of wearing a device nightly.
The Leadless Advantage
The Genio system distinguishes itself through its unique architecture. It is a leadless, battery-free neurostimulator. By providing bilateral hypoglossal nerve stimulation, it keeps the airway open by stimulating the nerves that control the tongue’s movement. Because it does not rely on bulky external batteries or long leads that can migrate or fracture, the device offers a more streamlined, patient-centric experience.
A Multidisciplinary Approach
The inclusion of both sleep medicine physicians and surgeons in the BREATHE study reflects the multidisciplinary nature of modern OSA care. While surgeons handle the implantation procedure, sleep physicians are crucial for titrating the therapy and managing the long-term monitoring of sleep architecture. This collaborative model ensures that the patient receives a holistic approach to their sleep health.
Perspectives from Leadership: A Commitment to Rigor
Olivier Taelman, CEO of Nyxoah, has emphasized that the launch of BREATHE is not merely a regulatory requirement, but a strategic commitment to clinical excellence.
"The first BREATHE implant marks the start of the largest prospective study of Genio to date," Taelman stated following the procedure in Florida. He highlighted that the study serves as the next logical step in building a robust, long-term evidence base for bilateral hypoglossal nerve stimulation in the US.
Taelman’s commentary underscores a critical shift in the medical device industry: the movement toward "evidence-based adoption." As he noted, "This is the evidence that patients, physicians, and payors expect. It reflects our commitment to clinical rigor beyond approval." By providing five years of data, Nyxoah is positioning itself to answer the tough questions regarding durability, cost-effectiveness, and sustained quality of life—factors that are increasingly scrutinized by insurance providers and hospital procurement boards.
Implications for the Future of Sleep Medicine
The launch of the BREATHE study carries profound implications for the broader sleep medicine landscape.
Impact on Payors and Reimbursement
In the US healthcare market, securing and maintaining reimbursement is intrinsically linked to the availability of long-term data. By proactively launching a five-year study, Nyxoah is effectively "future-proofing" its market access. Payors, who often hesitate to cover new technologies without extensive real-world validation, will likely view the BREATHE data as a gold-standard reference for the Genio system’s value proposition.
Setting a New Standard for Patient Outcomes
For patients, the prospect of a long-term, non-invasive alternative to CPAP is life-changing. If the BREATHE study continues to demonstrate the consistent effectiveness of the Genio system, it could lead to a significant shift in clinical guidelines for OSA treatment. Physicians may begin to offer hypoglossal nerve stimulation earlier in the treatment algorithm, rather than reserving it as a "last resort" for those who fail CPAP.
The Competitive Landscape
The medical device sector for OSA is highly competitive. With the BREATHE study, Nyxoah is setting a high bar for clinical transparency. By inviting scrutiny through a large-scale, multi-center prospective study, the company is signaling its confidence in the technology. This move not only differentiates Nyxoah from competitors but also reinforces the importance of post-market clinical follow-up in maintaining public trust.
Conclusion
As the BREATHE study begins its five-year journey, the eyes of the sleep medicine community will be watching closely. With the first patient already benefiting from the Genio system, the potential for this study to reshape the treatment landscape for obstructive sleep apnea is immense.
By combining the technical innovation of a leadless, battery-free device with the clinical rigor of a 229-patient prospective study, Nyxoah is doing more than just selling a product—they are documenting a transformation in patient care. As the data flows in over the coming years, the medical community will gain invaluable insights into the long-term viability of hypoglossal nerve stimulation, potentially providing millions of patients with a better night’s sleep and a healthier, more vibrant life.
The launch of BREATHE is, above all, a reminder that the best technology is that which is supported by evidence, validated by practitioners, and centered on the long-term needs of the patient. For Nyxoah, the path ahead is clear: document the success, prove the durability, and lead the way in the future of sleep medicine.
About the Author
